Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data?

The DNA testing company would sell for a fraction of its peak valuation of $6 billion to a biotech aiming to use its data ...

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

Regeneron Pharmaceuticals is purchasing genetics and biotechnology company 23andMe and has vowed to protect customer data ...

Regeneron Pharmaceuticals on Monday announced plans to purchase genetic testing company 23andMe for $256 million. The New York-based drugmaker is set to take over 23andMe after winning a bankruptcy ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as ...

It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...